FM
BBIO icon

Family Management’s BridgeBio Pharma BBIO Stock Holding History

Family Management’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-10,493
Closed -$492K – 183
2021
Q3 		$492K Buy
10,493
+4,954
+89% +$266K 0.14% 104
2021
Q2 		$338K Buy
+5,539
New +$316K 0.09% 133

Other funds holding BBIO

KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
AIG
American International Group New York $609M AUM 23.67% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Family Management's BBIO Position: Q4 2021 in Review

Family Management sold out of BridgeBio Pharma (BBIO) in Q4 2021, closing a stake of 10,493 shares — an estimated $492K sold.

Family Management first reported a position in BBIO in Q2 2021 and held it in 2 quarters. The position peaked at $492K in Q3 2021. 195 funds tracked by Wall St. Rank hold BBIO as of Q4 2021.

  • Family Management reported no remaining BridgeBio Pharma position as of Q4 2021 after selling out during the quarter.
  • Family Management sold 10,493 BridgeBio Pharma shares in Q4 2021, an estimated $492K.
  • Family Management first reported a position in BridgeBio Pharma in Q2 2021 and held it in 2 quarters.
  • Family Management's BridgeBio Pharma position peaked at $492K in Q3 2021.
  • 195 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q4 2021.

Based on Family Management's 13F filing for Q4 2021, filed 14 Feb 2022.